Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
AJ4ZW7pQMwfn6fcM
Listen
